ADMdx publishes work demonstrating the potential of ADMdx image analysis technology to detect Alzheimer’s disease and treatment effects in at-risk, enriched populations. Adults with Down Syndrome (DS) provide a potentially enriched population for the preclinical and prodromal evaluation of Alzheimer’s disease (AD) therapeutics due to their accelerated rate of amyloid plaque formation and development of AD. However, conducting clinical trials in this population requires the ability to identify subjects with a known stage of AD, as well as the capability to detect AD-specific treatment effects distinct from those upon DS. ADMdx technology has achieved differentiation of AD from DS within subjects using either MRI or FDG PET imaging, enabling study of AD interventional treatments. Work was performed in collaboration with Dr. Michael Rafii of the University of California, San Diego and the Alzheimer’s Disease Cooperative Study (ADCS). This work has been published in the June 2016 issue of Alzheimer’s & Dementia: Translational Research and Clinical Intervention.